What is HC Wainwright's Estimate for CORT Q1 Earnings?

Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) - Investment analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Corcept Therapeutics in a report released on Tuesday, May 27th. HC Wainwright analyst S. Ramakanth anticipates that the biotechnology company will earn $0.49 per share for the quarter. HC Wainwright currently has a "Buy" rating and a $145.00 target price on the stock. The consensus estimate for Corcept Therapeutics' current full-year earnings is $1.36 per share. HC Wainwright also issued estimates for Corcept Therapeutics' Q2 2026 earnings at $0.62 EPS, Q3 2026 earnings at $1.09 EPS and Q4 2026 earnings at $1.35 EPS.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The biotechnology company reported $0.17 EPS for the quarter, meeting the consensus estimate of $0.17. Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. The firm had revenue of $157.21 million during the quarter, compared to analysts' expectations of $177.93 million. During the same period in the prior year, the firm posted $0.25 earnings per share. The business's quarterly revenue was up 7.1% compared to the same quarter last year.

CORT has been the subject of several other reports. Canaccord Genuity Group increased their price target on Corcept Therapeutics from $130.00 to $142.00 and gave the company a "buy" rating in a research report on Tuesday, April 1st. Wall Street Zen cut Corcept Therapeutics from a "buy" rating to a "hold" rating in a research report on Wednesday, May 14th. Truist Financial set a $135.00 price target on Corcept Therapeutics in a research report on Tuesday, May 6th. Finally, Piper Sandler increased their price target on Corcept Therapeutics from $128.00 to $131.00 and gave the company an "overweight" rating in a research report on Thursday, April 3rd. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, Corcept Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $138.25.

Corcept Therapeutics Stock Up 0.6%

NASDAQ CORT traded up $0.45 during trading hours on Thursday, hitting $78.09. 1,203,879 shares of the company traded hands, compared to its average volume of 1,123,363. The business's 50-day moving average is $72.53 and its 200-day moving average is $63.28. Corcept Therapeutics has a twelve month low of $28.04 and a twelve month high of $117.33. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.64 and a current ratio of 3.70. The stock has a market capitalization of $8.28 billion, a price-to-earnings ratio of 61.98 and a beta of 0.22.

Institutional Trading of Corcept Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. increased its stake in shares of Corcept Therapeutics by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 10,115,624 shares of the biotechnology company's stock worth $509,726,000 after purchasing an additional 109,294 shares during the period. Parallel Advisors LLC increased its stake in shares of Corcept Therapeutics by 3.7% during the first quarter. Parallel Advisors LLC now owns 3,972,416 shares of the biotechnology company's stock worth $453,729,000 after purchasing an additional 142,784 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Corcept Therapeutics by 2.8% during the first quarter. Dimensional Fund Advisors LP now owns 2,136,510 shares of the biotechnology company's stock worth $243,708,000 after purchasing an additional 57,942 shares during the period. Arrowstreet Capital Limited Partnership increased its stake in shares of Corcept Therapeutics by 4.1% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,644,942 shares of the biotechnology company's stock worth $82,889,000 after purchasing an additional 64,321 shares during the period. Finally, Jacobs Levy Equity Management Inc. increased its stake in shares of Corcept Therapeutics by 12.5% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 1,376,881 shares of the biotechnology company's stock worth $69,381,000 after purchasing an additional 153,100 shares during the period. Institutional investors own 93.61% of the company's stock.

Insider Buying and Selling at Corcept Therapeutics

In other Corcept Therapeutics news, insider Sean Maduck sold 100,000 shares of the company's stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $100.54, for a total value of $10,054,000.00. Following the sale, the insider now owns 85,622 shares in the company, valued at $8,608,435.88. This represents a 53.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Joseph K. Belanoff sold 2,924 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $60.91, for a total value of $178,100.84. Following the completion of the sale, the chief executive officer now owns 3,019,411 shares in the company, valued at $183,912,324.01. This represents a 0.10% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 296,352 shares of company stock worth $24,908,205 over the last 90 days. Company insiders own 20.50% of the company's stock.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.